TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 1:10 p.m. Eastern Time at the Marriott Copley Place in Boston, MA.
Investors and interested parties can access the presentation through a webcast available on the 'Events and Presentations' section of TScan's website at ir.tscan.com. The webcast recording will remain accessible on the company's website for 90 days after the event.
TScan Therapeutics (Nasdaq: TCRX), un'azienda biotecnologica in fase clinica che sviluppa terapie cellulari T con TCR ingegnerizzati per il trattamento del cancro, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La presentazione è programmata per il 5 marzo 2025, alle 13:10 ora orientale presso il Marriott Copley Place di Boston, MA.
Investitori e parti interessate possono accedere alla presentazione tramite un webcast disponibile nella sezione 'Eventi e Presentazioni' del sito web di TScan all'indirizzo ir.tscan.com. La registrazione del webcast rimarrà accessibile sul sito dell'azienda per 90 giorni dopo l'evento.
TScan Therapeutics (Nasdaq: TCRX), una empresa biotecnológica en etapa clínica que desarrolla terapias con células T ingenierizadas con TCR para el tratamiento del cáncer, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La presentación está programada para el 5 de marzo de 2025, a la 1:10 p.m. hora del Este en el Marriott Copley Place en Boston, MA.
Los inversores y partes interesadas pueden acceder a la presentación a través de un webcast disponible en la sección 'Eventos y Presentaciones' del sitio web de TScan en ir.tscan.com. La grabación del webcast permanecerá accesible en el sitio web de la empresa durante 90 días después del evento.
TScan Therapeutics (Nasdaq: TCRX), 암 치료를 위한 TCR 엔지니어링 T 세포 요법을 개발하는 임상 단계의 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참가한다고 발표했습니다. 발표는 2025년 3월 5일 동부 표준시 기준 오후 1시 10분에 보스턴, MA의 Marriott Copley Place에서 예정되어 있습니다.
투자자 및 관심 있는 분들은 TScan 웹사이트의 '이벤트 및 발표' 섹션에서 제공되는 웹캐스트를 통해 발표에 접근할 수 있습니다. 웹캐스트 녹화는 이벤트 후 90일 동안 회사 웹사이트에서 계속 이용할 수 있습니다.
TScan Therapeutics (Nasdaq: TCRX), une entreprise biopharmaceutique en phase clinique développant des thérapies cellulaires T ingénierées par TCR pour le traitement du cancer, a annoncé sa participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. La présentation est prévue pour le 5 mars 2025 à 13h10, heure de l'Est au Marriott Copley Place à Boston, MA.
Les investisseurs et les parties intéressées peuvent accéder à la présentation via un webinaire disponible dans la section 'Événements et Présentations' du site Web de TScan à l'adresse ir.tscan.com. L'enregistrement du webinaire restera accessible sur le site de l'entreprise pendant 90 jours après l'événement.
TScan Therapeutics (Nasdaq: TCRX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das TCR-ingenierte T-Zelltherapien zur Krebsbehandlung entwickelt, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Die Präsentation ist für den 5. März 2025 um 13:10 Uhr Eastern Time im Marriott Copley Place in Boston, MA, geplant.
Investoren und interessierte Parteien können über einen Webcast auf die Präsentation zugreifen, der im Abschnitt 'Veranstaltungen und Präsentationen' auf der Website von TScan unter ir.tscan.com verfügbar ist. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung auf der Website des Unternehmens zugänglich.
- None.
- None.
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time.
A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
When is TScan Therapeutics (TCRX) presenting at the TD Cowen Healthcare Conference 2025?
How long will TScan Therapeutics' (TCRX) TD Cowen conference webcast be available?
Where can I watch TScan Therapeutics' (TCRX) TD Cowen conference presentation?
What type of therapies is TScan Therapeutics (TCRX) developing?
